View in EDS

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Saved in:
Bibliographic Details
Title: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Authors: Chanan-Khan, Asher1 Chanan-Khan.Asher@mayo.edu, Cramer, Paula2, Demirkan, Fatih3, Fraser, Graeme4, Silva, Rodrigo Santucci5, Grosicki, Sebastian6, Pristupa, Aleksander7, Janssens, Ann8, Mayer, Jiri9, Bartlett, Nancy L10, Dilhuydy, Marie-Sarah11, Pylypenko, Halyna12, Loscertales, Javier13, Avigdor, Abraham14, Rule, Simon15, Villa, Diego16, Samoilova, Olga17, Panagiotidis, Panagiots18, Goy, Andre19, Mato, Anthony19,20
Source: Lancet Oncology. Feb2016, Vol. 17 Issue 2, p200-211. 12p.
Database: Academic Search Ultimate
Description
ISSN:14702045
DOI:10.1016/S1470-2045(15)00465-9